Neurocrine Biosciences Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Neurocrine Bio. (NBIX) PT Raised to $90 at Cowen as Ingrezza Blows Past Expectations
November 2, 2017 6:26 AM EDTCowen analyst Phil Nadeau raised his price target on Neurocrine Bio. (NASDAQ: NBIX) to $90.00 (from $65.00) while maintaining an Outperform rating following Q3 Ingrezza sales of $45.8MM, over 4x consensus of $10.8MME, and largely reflected end-user demand.
"While Q4 will be impacted by... More



